All In Biotech

Drug Trial Radar · NCT02108288

Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers

Last checked: Nov 20, 2026Latest source record: Apr 22, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

30

Actual

Start

Apr 2014

Primary completion

May 2014

Study completion Aug 2014

Sponsor

Sponsor type
Industry
First posted
Apr 9, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Who can join
Male only, from 20 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

OPC-1085EL ophthalmic solution, carteolol long-acting ophthalmic solution or latanoprost ophthalmic solution are administered once daily for 7 days and the effect on the blood concentration of carteolol and latanoprost in OPC-1085EL ophthalmic solution by formulating the combination drug will be determined.

Conditions

  • Glaucoma
  • Ocular Hypertension

Interventions

  • OPC-1085EL ophthalmic solutionDrug

  • Carteolol long-acting ophthalmic solutionDrug

  • Latanoprost ophthalmic solutionDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax of CarteololTime frame: Day 1 and Day 7
  2. Cmax of Latanoprost AcidTime frame: Day 1 and Day 7

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Kansai Region, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.